Back to Search
Start Over
TAFA4-IL-10 axis potentiate immunotherapy for airway allergy by induction of specific regulatory T cells.
- Source :
- NPJ Vaccines; 10/31/2022, Vol. 7 Issue 1, p1-11, 11p
- Publication Year :
- 2022
-
Abstract
- Allergen-specific immunotherapy (AIT) is the main treatment for allergic diseases. The therapeutic efficacy of AIT has to be improved. Neuropeptides, such as TAFA4, have immune-regulating features. The objective of this study is to promote the efficacy of AIT in experimental allergic rhinitis (AR) by the concurrent use of TAFA chemokine as a family member 4 (TAFA4). In this study, an AR mouse model was developed using ovalbumin (OVA) as the specific antigen. The AR response was assessed in mice after treatment with AIT or/and TAFA4. We found that exposure to TAFA4 activated dendritic cells (DCs) in the airway tissues. Activation of DC by TAFA4 resulted in the expression of IL-10. TAFA4 also promoted the activities of c-Maf inducing protein. The FPR1-MyD88-AKT signal pathway was associated with the TAFA4-induced Il10 expression in the DCs. Co-administration of AIT/TAFA4 attenuated the AR response in mice by inducing antigen-specific Tr1 cells. In conclusion, TAFA4 induces the expression of IL-10 in DCs. Acting as an adjuvant, TAFA4 significantly improves AIT's therapeutic efficacy against AR by inducing antigen-specific Tr1 cells. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20590105
- Volume :
- 7
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- NPJ Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 159972750
- Full Text :
- https://doi.org/10.1038/s41541-022-00559-w